Scarica l'app Stockscreener
21.38
0.52%
0.11
Dopo l'orario di chiusura:
21.44
0.06
+0.28%
Precedente Chiudi:
$21.27
Aprire:
$21.27
Volume 24 ore:
831.24K
Relative Volume:
1.30
Capitalizzazione di mercato:
$960.66M
Reddito:
$681.75M
Utile/perdita netta:
$70.47M
Rapporto P/E:
14.74
EPS:
1.45
Flusso di cassa netto:
$173.19M
1 W Prestazione:
-1.66%
1M Prestazione:
-17.04%
6M Prestazione:
-20.52%
1 anno Prestazione:
+28.80%
Intervallo 1D:
$20.96
$21.77
Intervallo di 1 settimana:
$20.50
$21.85
Portata 52W:
$16.00
$27.98
Pacira Biosciences Inc Stock (PCRX) Company Profile
Nome
Pacira Biosciences Inc
Settore
Telefono
650-242-8052
Indirizzo
2000 SIERRA POINT PARKWAY, BRISBANE, NJ
Confronta PCRX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PCRX
Pacira Biosciences Inc
|
21.38 | 955.72M | 681.75M | 70.47M | 173.19M | 1.45 |
|
ZTS
Zoetis Inc
|
144.09 | 63.86B | 9.39B | 2.62B | 2.22B | 5.8121 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.44 | 41.80B | 29.96B | 957.25M | 4.77B | 0.2956 |
|
HLN
Haleon Plc Adr
|
9.27 | 40.88B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
20.48 | 22.98B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
445.43 | 19.53B | 3.08B | 1.24B | 1.07B | 25.61 |
Pacira Biosciences Inc Stock (PCRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-25 | Aggiornamento | Truist | Hold → Buy |
| 2025-01-30 | Aggiornamento | Truist | Sell → Hold |
| 2024-08-13 | Downgrade | Truist | Buy → Sell |
| 2024-08-12 | Downgrade | JP Morgan | Overweight → Underweight |
| 2024-08-12 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2024-08-12 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-08-12 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2024-07-03 | Downgrade | Barclays | Overweight → Equal Weight |
| 2024-03-07 | Ripresa | JP Morgan | Overweight |
| 2023-12-20 | Iniziato | Raymond James | Outperform |
| 2023-08-03 | Aggiornamento | TD Cowen | Market Perform → Outperform |
| 2023-01-31 | Ripresa | Wedbush | Outperform |
| 2022-10-21 | Ripresa | Jefferies | Buy |
| 2022-01-03 | Ripresa | JP Morgan | Overweight |
| 2021-07-26 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2021-04-21 | Ripresa | JP Morgan | Neutral |
| 2021-04-09 | Iniziato | Berenberg | Buy |
| 2021-04-07 | Ripresa | RBC Capital Mkts | Outperform |
| 2021-02-11 | Downgrade | Northland Capital | Outperform → Market Perform |
| 2021-01-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2020-09-21 | Aggiornamento | Northland Capital | Market Perform → Outperform |
| 2020-07-06 | Reiterato | Needham | Buy |
| 2020-05-27 | Iniziato | Guggenheim | Neutral |
| 2020-04-07 | Iniziato | Northland Capital | Outperform |
| 2020-03-20 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2020-02-24 | Reiterato | H.C. Wainwright | Buy |
| 2020-01-24 | Iniziato | SunTrust | Buy |
| 2020-01-23 | Iniziato | SunTrust | Buy |
| 2019-11-06 | Iniziato | BTIG Research | Buy |
| 2019-06-11 | Iniziato | Barclays | Overweight |
| 2019-05-06 | Aggiornamento | Mizuho | Underperform → Neutral |
| 2019-05-02 | Aggiornamento | Stifel | Sell → Hold |
| 2019-02-01 | Downgrade | Mizuho | Neutral → Underperform |
| 2018-08-06 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2018-04-09 | Reiterato | H.C. Wainwright | Buy |
| 2018-03-21 | Reiterato | Mizuho | Neutral |
| 2018-02-16 | Downgrade | Needham | Buy → Hold |
| 2018-01-19 | Iniziato | Seaport Global Securities | Buy |
| 2018-01-04 | Reiterato | Canaccord Genuity | Buy |
| 2018-01-03 | Iniziato | Leerink Partners | Mkt Perform |
Mostra tutto
Pacira Biosciences Inc Borsa (PCRX) Ultime notizie
Chart based analysis of Pacira BioSciences Inc. trendsJuly 2025 Reactions & Safe Capital Growth Tips - newser.com
Why Pacira BioSciences Inc. (82P) stock could outperform next yearJuly 2025 Volume & Community Consensus Picks - newser.com
Pacira BioSciences Inc. recovery potential after sell off2025 Market Overview & Community Consensus Stock Picks - newser.com
How to integrate Pacira BioSciences Inc. into portfolio analysis toolsTrade Risk Report & AI Based Buy and Sell Signals - newser.com
Building trade automation scripts for Pacira BioSciences Inc.2025 Momentum Check & Fast Moving Stock Watchlists - newser.com
Can a trend reversal in Pacira BioSciences Inc. lead to recoveryJuly 2025 Rallies & Stepwise Trade Signal Implementation - newser.com
Real time social sentiment graph for Pacira BioSciences Inc.2025 Geopolitical Influence & Reliable Breakout Stock Forecasts - newser.com
Is Pacira BioSciences Inc. stock poised for growthBuy Signal & Free Accurate Trade Setup Notifications - newser.com
Pacira to Report Third Quarter 2025 Financial Results on Thursday November 6, 2025 - markets.businessinsider.com
Pacira BioSciences Inc. stock retracement – recovery analysis2025 Growth vs Value & High Accuracy Buy Signal Tips - newser.com
Pacira Biosciences, Inc. Experiences Evaluation Revision Amidst Market Dynamics and Performance Trends - Markets Mojo
Pacira BioSciences (PCRX) Expected to Announce Quarterly Earnings on Wednesday - MarketBeat
Pacira BioSciences (Nasdaq: PCRX) sets Nov. 6 third-quarter results; call at 4:30 p.m. ET - Stock Titan
Will Pacira BioSciences Inc. stock keep outperforming rivalsMarket Sentiment Report & Technical Analysis for Trade Confirmation - newser.com
What is the fair value estimate for Pacira BioSciences Inc. (82P) stock in 2025Market Trend Review & Weekly Momentum Stock Picks - newser.com
Pacira BioSciences Presents Updated Three-Year Data Demonstrating Sustained Efficacy and Safety of PCRX-201 Gene Therapy for Patients with Moderate-to-Severe Osteoarthritis of the Knee - markets.businessinsider.com
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Pacira BioSciences, Inc. (PCRX) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Pacira BioSciences, Inc. Presents Updated Three-Year Data Demonstrating Sustained Efficacy and Safety of PCRX-201 Gene Therapy for Patients with Moderate-To-Severe Osteoarthritis of the Knee - MarketScreener
Pacira BioSciences (PCRX) Reports Promising Three-Year Findings for PCRX-201 - GuruFocus
Is Pacira BioSciences Inc. stock a buy on dipsForecast Cut & Smart Investment Allocation Insights - Fundação Cultural do Pará
Pacira Biosciences Increceives Paragraph IV notice from Qilu Pharmaceutical - MarketScreener
Pacira BioSciences receives patent challenge for EXPAREL from Chinese firm - Investing.com
Pacira BioSciences Notified of Abbreviated New Drug Application Filing from Qilu Pharmaceutical (Hainan) Co., Ltd. for EXPAREL® - The Manila Times
Pacira BioSciences Receives PIV Notice from Qilu Pharmaceutical Regarding Generic EXPAREL Patent Claims - Quiver Quantitative
Pacira Biosciences Inc Azioni (PCRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.18%
1.86%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):